![Morning Star](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915)
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
Morning Star,
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK…
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK…
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK…
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK…
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK…